These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21422518)

  • 21. Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?
    Bons N; Rieger F; Prudhomme D; Fisher A; Krause KH
    Genes Brain Behav; 2006 Mar; 5(2):120-30. PubMed ID: 16507003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fronto-temporal-lobe atrophy in early-stage Alzheimer's disease identified using an improved detection methodology.
    Farrow TF; Thiyagesh SN; Wilkinson ID; Parks RW; Ingram L; Woodruff PW
    Psychiatry Res; 2007 May; 155(1):11-9. PubMed ID: 17399959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-associated memory impairment and early Alzheimer's disease. Only time will tell the difference.
    Förstl H; Hentschel F; Sattel H; Geiger-Kabisch C; Besthorn C; Czech C; Mönning U; Beyreuther K
    Arzneimittelforschung; 1995 Mar; 45(3A):394-7. PubMed ID: 7763332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
    Terry AV; Buccafusco JJ
    J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Deficits in inhibitory processes in normal aging and patients with Alzheimer's disease: a review].
    Fournet N; Mosca C; Moreaud O
    Psychol Neuropsychiatr Vieil; 2007 Dec; 5(4):281-94. PubMed ID: 18048106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Workgroup on NAPA's scientific agenda for a national initiative on Alzheimer's disease.
    Alzheimer's Association Expert Advisory Workgroup on NAPA
    Alzheimers Dement; 2012 Jul; 8(4):357-71. PubMed ID: 22748940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive deficits in preclinical Alzheimer's disease.
    Small BJ; Mobly JL; Laukka EJ; Jones S; Bäckman L
    Acta Neurol Scand Suppl; 2003; 179():29-33. PubMed ID: 12603248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: diagnostic and differential diagnostic features.
    Kluger A; Gianutsos JG; Golomb J; Ferris SH; Reisberg B
    Int Psychogeriatr; 1997; 9 Suppl 1():307-16; discussion 317-21. PubMed ID: 9447451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease.
    Robertson IH
    Neurobiol Aging; 2013 Jan; 34(1):298-308. PubMed ID: 22743090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease.
    Kluger A; Gianutsos JG; Golomb J; Ferris SH; George AE; Franssen E; Reisberg B
    J Gerontol B Psychol Sci Soc Sci; 1997 Jan; 52B(1):P28-39. PubMed ID: 9008673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroinflammatory challenges compromise neuronal function in the aging brain: Postoperative cognitive delirium and Alzheimer's disease.
    Cortese GP; Burger C
    Behav Brain Res; 2017 Mar; 322(Pt B):269-279. PubMed ID: 27544872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenges of cognitive aging: integrating approaches from science to intergenerational relationships.
    Whitehouse P
    J Alzheimers Dis; 2013; 36(2):225-32. PubMed ID: 23619307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective attention in Alzheimer's disease.
    Foster JK
    Front Biosci; 2001 Feb; 6():D135-53. PubMed ID: 11171548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of information and communication technology devices for monitoring functional and cognitive decline in Alzheimer's disease clinical trials.
    Pillai JA; Bonner-Jackson A
    J Healthc Eng; 2015; 6(1):71-83. PubMed ID: 25708378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk.
    Frisardi V; Imbimbo BP
    J Alzheimers Dis; 2012; 30 Suppl 2():S1-4. PubMed ID: 22596269
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunologic and inflammatory mediators and cognitive decline in Alzheimer's disease.
    Ahluwalia N; Vellas B
    Immunol Allergy Clin North Am; 2003 Feb; 23(1):103-15. PubMed ID: 12645881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paying more attention to attention: towards more comprehensive cognitive translation using mouse models of Alzheimer's disease.
    Romberg C; Bussey TJ; Saksida LM
    Brain Res Bull; 2013 Mar; 92():49-55. PubMed ID: 22390982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current status of cognition-based interventions in Alzheimer's disease].
    Buschert VC; Teipel SJ; Hampel H; Bürger K
    Nervenarzt; 2009 Mar; 80(3):273-87. PubMed ID: 19229510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethical issues in the neurology of aging and cognitive decline.
    Klein E; Karlawish J
    Handb Clin Neurol; 2013; 118():233-42. PubMed ID: 24182382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Object recognition test for studying cognitive impairments in animal models of Alzheimer's disease.
    Bengoetxea X; Rodriguez-Perdigon M; Ramirez MJ
    Front Biosci (Schol Ed); 2015 Jun; 7(1):10-29. PubMed ID: 25961683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.